New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Analysis presented at American Thyroid Association Annual Meeting (ATA 2022) shows during a two-year period, 4.9% of patients who completed a full course of TEPEZZA were later prescribed a second